Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 357

1.

Testosterone therapy in men with prostate cancer: scientific and ethical considerations.

Morgentaler A.

J Urol. 2009 Mar;181(3):972-9. doi: 10.1016/j.juro.2008.11.031. Epub 2009 Jan 16. Review.

PMID:
19150547
2.

Testosterone therapy in men with prostate cancer: scientific and ethical considerations.

Morgentaler A.

J Urol. 2013 Jan;189(1 Suppl):S26-33. doi: 10.1016/j.juro.2012.11.028. Review.

PMID:
23234627
3.

Testosterone therapy in men with untreated prostate cancer.

Morgentaler A, Lipshultz LI, Bennett R, Sweeney M, Avila D Jr, Khera M.

J Urol. 2011 Apr;185(4):1256-60. doi: 10.1016/j.juro.2010.11.084. Epub 2011 Feb 22.

PMID:
21334649
4.

Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth.

Morgentaler A, Traish AM.

Eur Urol. 2009 Feb;55(2):310-20. doi: 10.1016/j.eururo.2008.09.024. Epub 2008 Sep 24. Review.

PMID:
18838208
5.

Testosterone and prostate cancer: revisiting old paradigms.

Isbarn H, Pinthus JH, Marks LS, Montorsi F, Morales A, Morgentaler A, Schulman C.

Eur Urol. 2009 Jul;56(1):48-56. doi: 10.1016/j.eururo.2009.03.088. Epub 2009 Apr 8. Review.

PMID:
19375844
6.

Testosterone therapy for men at risk for or with history of prostate cancer.

Morgentaler A.

Curr Treat Options Oncol. 2006 Sep;7(5):363-9. Review.

PMID:
16904053
7.

Rapidly shifting concepts regarding androgens and prostate cancer.

Morgentaler A.

ScientificWorldJournal. 2009 Jul 27;9:685-90. doi: 10.1100/tsw.2009.80. Review.

8.

Androgen replacement therapy after prostate cancer treatment.

Khera M.

Curr Urol Rep. 2010 Nov;11(6):393-9. doi: 10.1007/s11934-010-0143-3.

PMID:
20838944
9.

Prevention of prostate cancer by androgens: experimental paradox or clinical reality.

Algarté-Génin M, Cussenot O, Costa P.

Eur Urol. 2004 Sep;46(3):285-94; discussion 294-5. Review.

PMID:
15306098
10.

Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy.

Lane BR, Stephenson AJ, Magi-Galluzzi C, Lakin MM, Klein EA.

Urology. 2008 Dec;72(6):1240-5. doi: 10.1016/j.urology.2008.06.001. Epub 2008 Aug 9.

PMID:
18692874
11.

Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men.

Kaufman JM, Graydon RJ.

J Urol. 2004 Sep;172(3):920-2. Review.

PMID:
15310998
12.

Androgen replacement therapy and prostate safety.

Morales A.

Eur Urol. 2002 Feb;41(2):113-20. Review.

PMID:
12074396
13.

[Prostate carcinoma and testosterone: risks and controversies].

Rhoden EL, Averbeck MA.

Arq Bras Endocrinol Metabol. 2009 Nov;53(8):956-62. Review. Portuguese.

14.

A new era of testosterone and prostate cancer: from physiology to clinical implications.

Khera M, Crawford D, Morales A, Salonia A, Morgentaler A.

Eur Urol. 2014 Jan;65(1):115-23. doi: 10.1016/j.eururo.2013.08.015. Epub 2013 Aug 16. Review.

PMID:
24011426
15.

Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review.

Shabsigh R, Crawford ED, Nehra A, Slawin KM.

Int J Impot Res. 2009 Jan-Feb;21(1):9-23. doi: 10.1038/ijir.2008.31. Epub 2008 Sep 11. Review.

PMID:
18633357
16.

Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.

Coward RM, Simhan J, Carson CC 3rd.

BJU Int. 2009 May;103(9):1179-83. doi: 10.1111/j.1464-410X.2008.08240.x. Epub 2008 Dec 23.

17.

Prostate cancer in men using testosterone supplementation.

Gaylis FD, Lin DW, Ignatoff JM, Amling CL, Tutrone RF, Cosgrove DJ.

J Urol. 2005 Aug;174(2):534-8; discussion 538.

PMID:
16006887
18.

Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.

Demanes DJ, Brandt D, Schour L, Hill DR.

Am J Clin Oncol. 2009 Aug;32(4):342-7. doi: 10.1097/COC.0b013e31818cd277.

PMID:
19398902
19.

Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations.

Morales A, Black AM, Emerson LE.

BJU Int. 2009 Jan;103(1):62-4. doi: 10.1111/j.1464-410X.2008.07882.x. Epub 2008 Jul 29.

20.

Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer.

Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL.

Clin Cancer Res. 2005 Jul 1;11(13):4653-7.

Supplemental Content

Support Center